A new model for calculating invasive breast cancer drug risk (the CARE model) gives improved estimates of the number of breast cancers that might develop in African-American women 50 to 79 years of age. An earlier model had been based primarily on data in Caucasian women.
Read the rest of this entry »
In a new study, Merck’s drug vorinostat (Zolinza), a histone deacetylase inhibitor also known as suberoylanilide hydroxamic acid (SAHA), was able to cross the blood-brain barrier and reduce the development of large metastatic tumors in mice brains by 62% when compared with mice not receiving the drug. Vorinostat is approved to treat patients with cutaneous T-cell lymphoma.
